Literature DB >> 1746011

The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis.

M Morfini1, M Lee, A Messori.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1746011

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN： 0340-6245            Impact factor:   5.249


× No keyword cloud information.
  17 in total

1.  The price of enhanced half-life factor IX.

Authors:  Andrea Messori; Sabrina Trippoli
Journal:  Blood Transfus       Date:  2016-10-24       Impact factor: 3.443

2.  Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial.

Authors:  Elena Santagostino; Uri Martinowitz; Toshko Lissitchkov; Brigitte Pan-Petesch; Hideji Hanabusa; Johannes Oldenburg; Lisa Boggio; Claude Negrier; Ingrid Pabinger; Mario von Depka Prondzinski; Carmen Altisent; Giancarlo Castaman; Koji Yamamoto; Maria-Teresa Álvarez-Roman; Christine Voigt; Nicole Blackman; Iris Jacobs
Journal:  Blood       Date:  2016-01-11       Impact factor: 22.113

Review 3.  Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia.

Authors:  S Björkman; E Berntorp
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring.

Authors:  S Björkman; V S Blanchette; K Fischer; M Oh; G Spotts; P Schroth; S Fritsch; L Patrone; B M Ewenstein; P W Collins
Journal:  J Thromb Haemost       Date:  2010-04       Impact factor: 5.824

Review 5.  Management of factor VIII inhibitors.

Authors:  Donna M Dimichele
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

6.  Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.

Authors: 
Journal:  CMAJ       Date:  1995-07-15       Impact factor: 8.262

7.  Pharmacokinetics of factor IX in patients with haemophilia B. Methodological aspects and physiological interpretation.

Authors:  S Björkman; M Carlsson; E Berntorp
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

8.  Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients.

Authors:  Elena Santagostino; Claude Negrier; Robert Klamroth; Andreas Tiede; Ingrid Pabinger-Fasching; Christine Voigt; Iris Jacobs; Massimo Morfini
Journal:  Blood       Date:  2012-08-02       Impact factor: 22.113

9.  Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial.

Authors:  Gili Kenet; Hervé Chambost; Christoph Male; Thierry Lambert; Susan Halimeh; Tatiana Chernova; Maria Elisa Mancuso; Julie Curtin; Christine Voigt; Yanyan Li; Iris Jacobs; Elena Santagostino
Journal:  Thromb Haemost       Date:  2016-09-01       Impact factor: 5.249

10.  Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients.

Authors:  Kathelijn Fischer; Ronan Pendu; Carina J van Schooten; Karin van Dijk; Cécile V Denis; H Marijke van den Berg; Peter J Lenting
Journal:  PLoS One       Date:  2009-08-25       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.